Lilly announces replacements for two retiring executives

Two of Eli Lilly and Co.’s top leaders will retire at the end of this year, and the Indianapolis-based drugmaker will fill their posts by promoting from within.

Bryce Carmine, president of Lilly’s bio-medicines division, and Frank Deane, president of Lilly’s global manufacturing operations, both will retire on Dec. 31. They have worked at Lilly for 36 and 33 years, respectively.

In Carmine’s place, the president of Lilly’s U.S. subsidiary, Dave Ricks, will become chief of the bio-medicines unit. That unit oversees sales in the United States, Europe and Japan of some of Lilly’s most lucrative drugs, including the antipsychotic Zyprexa, the antidepressant Cymbalta and the anti-impotence pill Cialis.

Succeeding Deane will be Maria Crowe, who is currently the senior vice president for global drug product manufacturing. Crowe, who has managed Lilly plants in Ireland, Puerto Rico and Lafayette, Ind., will now oversee all 22 of its manufacturing and distribution sites as well as its contract manufacturing relationships.

Lilly also announced that Alex Azar, its vice president of U.S. managed healthcare services, will replace Ricks as head of Lilly USA. Azar, along with Ricks and Crowe, will move into their new positions on Jan. 1.

"We'll certainly miss Bryce and Frank and the extraordinary leadership they provided," said Lilly CEO John Lechleiter in a prepared statement. "At the same time, we're very fortunate to have talented leaders who are well-prepared and ready to step into these critical roles."

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}